论文部分内容阅读
糖尿病是胰岛素分泌异常,葡萄糖通过非酶促反应,致人体多组织多脏器细胞糖基化改变,如血液中红蛋白糖基化成为不可逆的糖化血红蛋白(HbAlc)。临床通过监测全血中血红蛋白中的糖化血红蛋白含量,评价红细胞半衰期近60 d的血糖浓度变化,判断糖尿病中期用药疗效,结合尿微量白蛋白(mAlb)、血清胱抑素C(CysC)及β2微球蛋白(β2-MG)检测[1],观察糖尿病引起的心脑血管病的发展进程及非传染
Diabetes is an abnormal insulin secretion. Glucose, through non-enzymatic reaction, causes glycosylation of multi-tissue and multiple organs in the human body, such as glycosylation of hemoglobin into irreversible glycosylated hemoglobin (HbAlc). Clinical monitoring of hemoglobin in hemoglobin by measuring the content of hemoglobin, erythrocytic half-life evaluation of nearly 60 d of blood glucose concentration changes, to determine the efficacy of diabetes mellitus, combined with urine microalbumin (mAlb), serum cystatin C (CysC) and β2 micro Globulin (β2-MG) test [1], to observe the development of diabetes-induced cardiovascular and cerebrovascular disease and non-contagious